Stocklytics Platform
Asset logo for symbol LGND
Ligand Pharmaceuticals
LGND72
$99.99arrow_drop_up1.04%$1.03
Asset logo for symbol LGND
LGND72

$99.99

arrow_drop_up1.04%

Income Statement (LGND)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT$2.98M$953.00K$15.22M-$5.97M$14.20M
EBITDA$12.23M$9.87M$23.45M$2.56M-$16.78M
gross Profit$19.91M$26.43M$29.38M$24.69M$40.26M
NET Income$86.13M$18.18M-$12.79M$2.29M$41.94M
total Revenue$30.97M$28.10M$32.86M$26.36M$43.97M

Balance Sheet (LGND)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$43.89M-$16.78M-$12.94M-$207.37M-$193.98M
stockholders Equity$806.52M$700.91M$665.40M$664.89M$646.31M
total Assets$913.86M$833.06M$769.21M$758.10M$811.07M
total Debt$6.19M$6.16M$6.32M$11.67M$88.67M
total Liabilities$107.34M$130.70M$103.80M$93.21M$164.75M

Cash Flow (LGND)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$12.22M$5.31M$3.27M-$67.75M-$775.00K
free Cash Flow$18.58M-$42.68M$7.15M-$285.00K$31.53M
investing Cash Flow---$7.55M$10.54M
operating Cash Flow$18.69M$8.06M$7.64M-$82.00K$33.94M

Ligand Pharmaceuticals (LGND) Financials

Ligand Pharmaceuticals Inc (LGND) is a biopharmaceutical company that focuses on developing and acquiring royalty-generating assets in the areas of oncology, immunology, and liver disease. The company's income statement reveals its financial performance over a specific period of time. It provides information on the company's revenues, expenses, and net income. For example, the income statement may show that Ligand Pharmaceuticals Inc had a total revenue of $500 million, with a gross profit of $300 million. After deducting operating expenses, such as research and development costs, the company may report an EBIT (earnings before interest and taxes) of $200 million. This measure indicates the company's profitability before taking into account interest and tax expenses. EBITDA (earnings before interest, taxes, depreciation, and amortization) is another measure that provides insight into a company's operating performance. Ligand Pharmaceuticals Inc may report an EBITDA of $250 million, which represents its earnings before considering non-cash expenses and other deductions. This metric is useful for comparing the financial performance of different companies, as it removes the impact of non-operational factors such as depreciation and amortization. Net income from stockholders refers to the profit generated by the company after accounting for all expenses and taxes. Ligand Pharmaceuticals Inc may report a net income from stockholders of $150 million, which represents the amount available to be distributed to shareholders in the form of dividends or reinvested into the company. The company's balance sheet provides a snapshot of its financial position at a specific point in time. It includes information on the company's assets, liabilities, and stockholders' equity. For example, Ligand Pharmaceuticals Inc may report total assets of $1 billion, which includes cash equivalents, investments, and property, plant, and equipment. The balance sheet also reveals the company's liabilities, such as total debt, which represents the amount of money the company owes to creditors. Ligand Pharmaceuticals Inc may report a total debt of $500 million, which includes both short-term and long-term obligations. The difference between the company's assets and liabilities is known as stockholders' equity. Ligand Pharmaceuticals Inc may have stockholders' equity of $500 million, which represents the shareholders' ownership in the company. Cash flow refers to the movement of cash in and out of the company over a specific period of time. Ligand Pharmaceuticals Inc may report a positive operating cash flow of $300 million, indicating that the company generated cash from its core operations. The company's financing cash flow represents the cash flow resulting from activities such as issuing or repurchasing shares and paying dividends. Ligand Pharmaceuticals Inc may have a negative financing cash flow of $200 million, indicating that the company used cash to finance its operations. Investing cash flow represents the cash flow resulting from activities such as purchasing or selling assets or making investments. Ligand Pharmaceuticals Inc may report a positive investing cash flow of $100 million, indicating that the company generated cash from its investing activities. Free cash flow is a measure of the company's cash available for distribution to investors or for reinvestment. Ligand Pharmaceuticals Inc may have a free cash flow of $150 million, calculated by subtracting capital expenditures from operating cash flow. The company's financial statements provide valuable insights into its performance, liquidity, and overall financial health.

Ligand Pharmaceuticals Inc's financial position is reflected in its balance sheet. The balance sheet reveals the company's assets, liabilities, and stockholders' equity at a specific point in time. For example, Ligand Pharmaceuticals Inc may have total assets of $1 billion, which includes cash equivalents, investments, and property, plant, and equipment. The company's liabilities include total debt of $500 million, representing the amount of money the company owes to creditors. The difference between the company's assets and liabilities is known as stockholders' equity, which may be $500 million. This represents the shareholders' ownership in the company. Cash flow refers to the movement of cash in and out of the company over a specified period of time. Ligand Pharmaceuticals Inc may have a positive operating cash flow of $300 million, indicating that the company generated cash from its core operations. The company's financing cash flow represents the cash flow resulting from activities such as issuing or repurchasing shares and paying dividends. Ligand Pharmaceuticals Inc may have a negative financing cash flow of $200 million, indicating that the company used cash to finance its operations. Investing cash flow represents the cash flow resulting from activities such as purchasing or selling assets or making investments. Ligand Pharmaceuticals Inc may report a positive investing cash flow of $100 million, indicating that the company generated cash from its investing activities. Free cash flow is a measure of the company's cash available for distribution to investors or for reinvestment. Ligand Pharmaceuticals Inc may have a free cash flow of $150 million, calculated by subtracting capital expenditures from operating cash flow. The company's financial statements provide valuable insights into its performance, liquidity, and overall financial health.

add Ligand Pharmaceuticals  to watchlist

Keep an eye on Ligand Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level